THORASYS Exhibits at ATS 2011

The International Conference of the American Thoracic Society (ATS) recently took place in Denver, Colorado, attracting an estimated 12,000 clinicians and scientists from the fields of respiratory, critical care and sleep medicine. For the first time in our corporate history, Thorasys was represented in the ATS exhibit hall to publicly present a pre-production prototype of our tremoFlo Oscillation Spirometer at a major international conference. We received a lot of visitors to our booth, and we would like to thank all of those who stopped by for this strong and enthusiastic response!

Outside the exhibit hall, we were also happy to see that the Forced Oscillation Technique (FOT) continues to show strong momentum, with a continuously increasing number of studies and presentations using this technique. With many of these studies employing large and/or "home-made" FOT devices, the need for a portable commercial FOT device like the tremoFlo was more evident than ever.  

As we continue to push towards the commercial release of the tremoFlo, we look forward to seeing you again at the European Respiratory Society (ERS) meeting in Amsterdam in September, and at ATS 2012 in San Francisco. In the meantime, don't hesitate to write a comment on this blog or send us your questions at info@thorasys.com.

Welcome to THORASYS

Hello, and welcome to the Thorasys blog!

Thorasys Thoracic Medical Systems is an innovative medical device start-up located in Halifax, Nova Scotia, Canada. Our activities focus on the development of the tremoFlo, a novel medical device for the diagnosis and monitoring of respiratory diseases such as Asthma and COPD. The tremoFlo is scheduled to reach the market in 2012.

The tremoFlo is a small, portable device that uses the Forced Oscillation Technique (FOT) to provide accurate measurements of airway resistance and reactance. The tremoFlo does not require patient effort or cooperation and can hence be used comfortably by a wide range of paediatric, adult and elderly subjects, including mobility impaired patients and those who are unable to perform a voluntary manoeuvre. The tremoFlo can potentially replace so-called "spirometers" that require patient effort and cooperation to assess lung function.

The tremoFlo is currently being field tested at several sites throughout North America, and field testing in Europe is expected to start soon. This blog will provide regular updates about the tremoFlo development as we prepare for commercial release in several jurisdictions in the first half of 2012.